公开(公告)号：US20230265095A1

公开(公告)日：2023-08-24

申请号：US18051654

申请日：2022-11-01

Applicant: H. Lundbeck A/S

Inventor： Thomas VETTER ,  Martin JUHL ,  HEIDI LOPEZ DE DIEGO ,  Cheryl A. GRICE ,  John J.M. WIENER ,  Daniel J. BUZARD ,  Amy ALLAN ,  Susana DEL RIO GANCEDO ,  Samuel George ANDREW ,  Antonio CINCOTTI ,  Adam Ross PATTERSON ,  Richard James EDWARDS

IPC: C07D471/10

CPC classification number: C07D471/10 ,  C07B2200/13

Abstract: Described herein are new crystalline forms of the MAGL inhibitor 1-(1-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)b enzyl)-1,8-diazaspiro[4.5]decane-8-carbonyl)-1H-pyrazole-3-carboxylic acid, or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20180319786A1

公开(公告)日：2018-11-08

申请号：US15772702

申请日：2016-11-01

Applicant: H. Lundbeck A/S

Inventor： John Paul KILBURN ,  Allen T. HOPPER ,  Martin JUHL

IPC: C07D417/14 ,  A61P29/00

CPC classification number: C07D417/14 ,  A61P29/00 ,  C07D417/04

Abstract: The present invention provides (S)-N-(2-(4-chlorophenyl)-2-morpholinoethyl)-2-(pyrimidin-2-yl)-4-(trifluoro-methyl)thiazole-5-carboxamide as P2X7 inhibitor, its use as a medicament, and a convenient enantiomeric synthesis protocol for the preparation of (S)-N-(2-(4-chlorophenyl)-2-morpholinoethyl)-2-(pyrimidin-2-yl)-4-(trifluoromethyl)thiazole-5-carboxamide.